arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Spyre Therapeutics, Inc.

SYRE

$104.92 ▲ +1.60 (+1.55%) at close

13 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

Spyre Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -29.3% ↗

FCF / Share None

Trailing P/E —

Price / Book 11.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

13-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-155.20M

↑ +25.4% —

FCF / Share Free cash flow per share

$-14.49

↓ -1422.6% —

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Revenue Growth YoY (%)	—	N/M	-62.0% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-874%)	-87.6% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1195%)	—	—	N/M	-25.3% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-416%)	—	—	—	—	—
EPS Growth YoY (%)	—	—	-4861.6% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	1.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	25.4% Excellent ↑ Excellent Improving Year-over-year change in net income	38.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-304.2% Weak ↓ Weak Declining Year-over-year change in net income	-27.4% Weak ↓ Weak Declining Year-over-year change in net income	18.7% Good ↑ Good Improving Year-over-year change in net income	-3.4% Weak ↑ Weak Improving Year-over-year change in net income	-76.5% Weak ↓ Weak Declining Year-over-year change in net income	-62.8% Weak ↓ Weak Declining Year-over-year change in net income	-25.5% Weak ↑ Weak Improving Year-over-year change in net income	-92.1% Weak Weak Year-over-year change in net income	-9.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	—	—	-1422.6% Weak Weak Year-over-year change in free cash flow	-15.2% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	—	—	—	—	68.9% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—
Revenue CAGR 5Y (%)	—	—	-25.6% Weak Weak Compound annual revenue growth over 5 years	-14.9% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Operating Margin (%) (%)	—	—	—	—	-350.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2436%)	—	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—
Profit Margin (%) (%)	—	—	—	—	-351.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3026%)	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	—	—	—	—	-289.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	-484.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	1.09x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.29x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Return on Invested Capital (%)	-29.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-40.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-131.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-168.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-78.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-58.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-105.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-43.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-27.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	40.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	61.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-26.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-70.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-119.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-59.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-50.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-96.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-58.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-49.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-29.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-21.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-245%)	-40.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-368%)	-184.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1327%)	-166.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1211%)	-78.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-623%)	-57.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-486%)	-130.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-968%)	-65.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-538%)	-54.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-461%)	-34.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-330%)	50.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+239%)	90.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+501%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Net Debt (USD)	$-85.72M	$-89.42M	$-188.89M	$-34.86M	$-15.14M	$-90.09M	$-19.25M	$-22.46M	$-12.82M	$-47.75M	$-29.29M	$-2.62M	$-4.60M

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Revenue per Share (USD)	—	—	$0.13	$0.03	$0.29	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	—	—	$-49.12	$-0.99	$-1.00	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	—	—	$-14.49	$-0.95	$-0.83	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$9.15	$8.59	$5.10	$0.77	$1.70	$2.92	$2.07	$2.79	$3.02	$4.69	$-29.32	—	—
Tangible Book Value per Share (USD)	$9.15	$8.59	$5.10	$0.77	$1.70	$2.92	$2.07	$2.79	$3.02	$4.69	$-29.32	—	—
Basic Weighted Avg Shares (shares)	—	—	6.90M	84.28M	65.74M	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Working Capital (USD)	$719.10M	$554.41M	$309.55M	$47.60M	$78.75M	$133.35M	$56.15M	$66.43M	$49.36M	$62.46M	$35.76M	—	—
Total Equity (USD)	$715.24M	$517.80M	$184.02M	$50.30M	$83.94M	$139.83M	$60.08M	$67.43M	$50.34M	$62.97M	$-22.21M	$-11.47M	$-1.27M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$0.00	$886.00K	$2.33M	$18.74M	$0.00	$0.00	$3.89M	$5.21M	—	—	—	—
Depreciation Expense (USD)	$0.00	$0.00	$744.00K	$1.57M	$1.58M	$996.00K	$418.00K	$293.00K	$249.00K	$132.00K	$89.00K	$19.00K	—
Net Income, GAAP (USD)	$-155.20M	$-208.02M	$-338.79M	$-83.81M	$-65.80M	$-80.89M	$-78.25M	$-44.35M	$-27.24M	$-21.70M	$-11.29M	$-10.35M	—
Operating Cash Flow (USD)	$-169.25M	$-157.41M	$-99.91M	$-80.14M	$-53.72M	$-75.78M	$-65.69M	$-32.19M	$-24.61M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 47 quarters

Spyre Therapeutics, Inc.

Analytical Summary

13-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare SYRE with peers